Google
PLRX — PLIANT THERAPEUTICS INC (Healthcare >> Biotechnology)
PLRX FAQ
What is PLRX's ROE?
PLIANT THERAPEUTICS INC reports a Return on Equity (ROE) of -68.55%.
What is PLRX's dividend yield?
PLIANT THERAPEUTICS INC offers a dividend yield of 0.00%.
What is PLRX's Deepscope Quality Score?
Deepscope rates PLRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PLRX?
Deepscope's AI Timing Score for PLRX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PLRX belong to?
PLIANT THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.15
Price
-0.02
(-1.71%)
Day Change
|
|
|---|
PLRX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.15 |
| PBV / Sector |
0.44 / 4.63
GREAT
|
| Earning Per Share | -1.80 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.63 M
GREAT
|
| Average 1W Daily Value |
0.95 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:06 |
| Symbol | PLRX |
| Name | PLIANT THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 61.92 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 72.45 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 481 6770
Website: https://pliantrx.com
Sector: Healthcare >> Biotechnology
Description: Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
